UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

Phase 1 Completed 30 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with irinotecan in treating patients who have advanced solid tumors.

Timeline

Start: 2002-08
Primary completion: 2006-02
Completion: —

Publications

Results Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Mar;61(3):423-33. doi: 10.1007/s00280-007-0485-9. Epub 2007 Apr 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	60 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	90 mg/m2	Intravenous
Subject	UCN-01	Small molecule	25 mg/m2	Intravenous
Subject	UCN-01	Small molecule	35 mg/m2	Intravenous
Subject	UCN-01	Small molecule	45 mg/m2	Intravenous

UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications